Which companies overlap with Stichting Hemato-Oncologie voor Volwassenen Nederland's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Asan Medical Center, Eye & ENT Hospital of Fudan University, Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/stichting-hemato-oncologie-voor-volwassenen-nederland.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Stichting Hemato-Oncologie voor Volwassenen Nederland — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stichting Hemato-Oncologie voor Volwassenen Nederland pipeline: 0 marketed, 0 filed, 4 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 5 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Daunorubicin or Idarubicin	Daunorubicin or Idarubicin	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA	Oncology
Venetoclax 400	Venetoclax 400	phase 3	BCL-2 inhibitor	BCL-2	Oncology
Placebo for AG-221	Placebo for AG-221	phase 3			Oncology
Placebo for AG-120	Placebo for AG-120	phase 3			Oncology

Therapeutic area mix

Oncology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Asan Medical Center · 2 shared drug classes
Eye & ENT Hospital of Fudan University · 2 shared drug classes
Janssen Research & Development, LLC · 2 shared drug classes
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 2 shared drug classes
The First Affiliated Hospital with Nanjing Medical University · 2 shared drug classes
Amgen · 1 shared drug class
Akeso · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Stichting Hemato-Oncologie voor Volwassenen Nederland:

Cite this brief

Drug Landscape (2026). Stichting Hemato-Oncologie voor Volwassenen Nederland — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stichting-hemato-oncologie-voor-volwassenen-nederland. Accessed 2026-05-17.